Literature DB >> 32409418

Reprogramming immunosuppressive tumour-associated dendritic cells with GADD45β inhibitors.

Sultan Rajpoot1, Jason Bennett1, Guido Franzoso1, Daniela Verzella1, Federica Begalli1, Daria Capece1, Daniel D'Andrea1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32409418      PMCID： PMC7243562          DOI： 10.7861/clinmed.20-2-s116

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  5 in total

Review 1.  Cancer immunotherapy via dendritic cells.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 2.  Tumor-infiltrating dendritic cells in cancer pathogenesis.

Authors:  Jo Marie Tran Janco; Purushottam Lamichhane; Lavakumar Karyampudi; Keith L Knutson
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

Review 3.  Clinical use of dendritic cells for cancer therapy.

Authors:  Sébastien Anguille; Evelien L Smits; Eva Lion; Viggo F van Tendeloo; Zwi N Berneman
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

4.  Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.

Authors:  Hirotomo Harimoto; Masumi Shimizu; Yohko Nakagawa; Katsuhisa Nakatsuka; Ayako Wakabayashi; Choitsu Sakamoto; Hidemi Takahashi
Journal:  Immunol Cell Biol       Date:  2013-09-10       Impact factor: 5.126

5.  GADD45β Loss Ablates Innate Immunosuppression in Cancer.

Authors:  Daniela Verzella; Jason Bennett; Mariafausta Fischietti; Anil K Thotakura; Camilla Recordati; Fabio Pasqualini; Daria Capece; Davide Vecchiotti; Daniel D'Andrea; Barbara Di Francesco; Marcella De Maglie; Federica Begalli; Laura Tornatore; Salvatore Papa; Toby Lawrence; Stuart J Forbes; Antonio Sica; Edoardo Alesse; Francesca Zazzeroni; Guido Franzoso
Journal:  Cancer Res       Date:  2017-12-26       Impact factor: 12.701
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.